Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Stock Has Average Target Price of $37.25 According to Brokerages

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) have been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $37.25.

ZLAB has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Zai Lab in a report on Tuesday, October 27th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a report on Tuesday, October 6th. Citigroup upped their target price on Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, Wall Street Zen raised Zai Lab from a “sell” rating to a “hold” rating in a research note on Saturday, September 26th.

Insider Buying and Selling at Zai Lab

In other news, Director Richard Gaynor purchased 1,228 shares of the business’s stock in a transaction dated Tuesday, November 10th. The stock was acquired at an average price of $27.19 per share, for a total transaction of $33,389.32. Following the acquisition, the director directly owned 81,965 shares of the company’s stock, valued at approximately $2,228,628.35. This represents a 1.52% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.88% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zai Lab

A number of institutional investors have recently made changes to their positions in ZLAB. Nantahala Capital Management LLC raised its stake in shares of Zai Lab by 65.0% in the 3rd quarter. Nantahala Capital Management LLC now owns 330,000 shares of the company’s stock valued at $8,692,000 after acquiring an additional 130,000 shares during the period. Nan Fung Trinity HK Ltd. raised its position in Zai Lab by 106.9% in the third quarter. Nan Fung Trinity HK Ltd. now owns 293,966 shares of the company’s stock valued at $7,743,000 after purchasing an additional 151,883 shares during the period. Alps Advisors Inc. raised its position in Zai Lab by 34.9% in the third quarter. Alps Advisors Inc. now owns 148,993 shares of the company’s stock valued at $3,924,000 after purchasing an additional 38,562 shares during the period. Seven Fleet Capital Management LP grew its stake in shares of Zai Lab by 74.7% in the second quarter. Seven Fleet Capital Management LP now owns 136,016 shares of the company’s stock valued at $2,584,000 after buying an additional 58,158 shares in the last quarter. Finally, Headlands Technologies LLC raised its holdings in shares of Zai Lab by 142.0% in the 2nd quarter. Headlands Technologies LLC now owns 68,010 shares of the company’s stock valued at $1,292,000 after buying an additional 39,901 shares during the period. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Zai Lab Trading Down 5.5%

NASDAQ:ZLAB traded down $1.44 during trading hours on Thursday, hitting $24.60. 1,224,327 shares of the stock were exchanged, compared to its average volume of 1,295,968. The firm’s fifty day moving average price is $24.62 and its 200 day moving average price is $21.26. Zai Lab has a 52-week low of $15.96 and a 52-week high of $29.02. The company has a market cap of $3.08 billion, a P/E ratio of -13.74 and a beta of 0.77.

Zai Lab (NASDAQ:ZLAB) last announced its earnings results on Thursday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.18. The company had revenue of $108.21 million for the quarter, compared to analysts’ expectations of $107.90 million. Zai Lab had a negative net margin of 44.91% and a negative return on equity of 31.15%. Equities analysts expect that Zai Lab will post -2.19 EPS for the current fiscal year.

Latest Zai Lab News

Here’s some of the latest news about ZLAB:

• Positive Sentiment: Five Zai Lab medicines were included in China’s 2026 National Reimbursement Drug List: KarXT and VYVGART Hytrulo® for the first time, plus three renewals covering oncology and infectious-disease treatments. Broader reimbursement could improve patient access and support commercial growth, though the reports do not specify the financial impact or reimbursement pricing. Article: Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo in China’s 2026 National Reimbursement Drug List
• Positive Sentiment: Zai Lab reported positive first-in-human results for ZL-1503, its investigational bispecific antibody for atopic dermatitis, with rapid and sustained inhibition of key biomarkers. The data support further development and potential quarterly maintenance dosing, but the candidate remains early in clinical testing. Article: Zai Lab Presents Positive First-in-Human Data for ZL-1503
• Positive Sentiment: Director Richard Gaynor bought 1,228 shares at an average $27.19, increasing his position by 1.52%. The purchase may be viewed as a modest confidence signal. SEC filing: Director share purchase

About Zai Lab

Zai Lab is a biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases. Its research and development programs focus on oncology, immunology, neuroscience and infectious diseases. Founded in 2014 by biopharmaceutical executive Samantha Du, the company is headquartered in Shanghai and operates in China and the United States. It advances its own drug candidates and works with international partners to develop and bring therapies to market. Zai Lab’s portfolio includes medicines and development programs for cancers and other conditions, including therapies introduced through licensing and collaboration agreements.